TrialThe Lancet. Oncology2017

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.

Kevin J Harrington et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.